Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma



Duell, Johannes, Maddocks, Kami J, Gonzalez-Barca, Eva, Jurczak, Wojciech, Liberati, Anna Marina, de Vos, Sven, Nagy, Zsolt, Obr, Ales, Gaidano, Gianluca, Abrisqueta, Pau
et al (show 11 more authors) (2021) Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. .

Access the full-text of this item by clicking on the Open Access link.
Item Type: Conference or Workshop Item (Unspecified)
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Depositing User: Symplectic Admin
Date Deposited: 12 Jul 2021 09:44
Last Modified: 19 May 2022 02:17
DOI: 10.3324/haematol.2020.275958
Open Access URL: https://doi.org/10.3324/haematol.2020.275958
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3129744